Optimizing Propranolol Therapy for Infantile Hemangiomas: The Role of the Multidisciplinary Team.

BACKGROUND

Oral propranolol therapy is currently the first choice for infants with infantile hemangiomas (IHs) requiring systemic treatment. This study aims to evaluate the safety and effectiveness of oral propranolol therapy for IHs and to assess the role of a multidisciplinary medical team in supporting optimal treatment.

MATERIALS AND METHODS

Clinical data were retrospectively reviewed from medical records in 150 Japanese infants with IH treated with propranolol orally at Toranomon Hospital. Patients with problematic IH, such as tumor-type IH or IH with ulceration, were eligible for inclusion. Treatment was managed by a medical team consisting of pediatricians, dermatologists, pediatric nurses, pharmacists, and nutritionists. Patients' general conditions and vital signs, such as blood pressure, pulse rate, respiratory rate, and blood sugar, were closely monitored before, one hour, and two hours after drug administration.

RESULTS

Close collaboration among multidisciplinary medical team members allowed for accurate patient evaluation, contributing to the early detection of side effects, even if asymptomatic. When side effects were suspected, pediatricians and dermatologists discussed the need to reduce or discontinue the medication. Of the 150 patients, no one experienced severe side effects. Although five cases (3.3%) were suspected of having mild side effects (i.e., hypotension, n = 3; hypotension and hypoglycemia, n = 1; inspiratory stridor, n = 1), treatment could be continued by adjusting the dosage. One hundred twenty patients have completed the oral propranolol therapy with successful outcomes.

CONCLUSIONS

This study provided additional evidence of the safety and effectiveness of oral propranolol therapy in 150 Japanese infants with IH. A well-functioning multidisciplinary medical team is essential for optimal patient treatment.